OnKure is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that include selective inhibitors of histone deacetylases (HDACs). In pre-clinical models of both hematological and solid tumor cancers, our lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies.
Our best in class approach has produced Class 1 selective inhibitors that are orally active with potencies that rival Istodax (Romidepsin). In addition to the Class-1 targeting OKI-179, we are advancing the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. It has been demonstrated in pre-clinical models of non-Hodgkin’s lymphoma that selective HDAC3 inhibition can restore immune surveillance without triggering undesirable hematopoiesis effects. We have also identified selective HDAC6 inhibitors that are among the most potent and selective agents reported to date.
OnKure operates as a virtual organization, relying on a group of veteran consultants and advisors to coordinate many of our pre-clinical and clinical development activities. This lean operating model, which also leverages our Chinese subsidiary, Peak Precision Medicine, allows us to retain considerable flexibility in the development of our products while minimizing capital expenditures and unnecessary overhead.